New Products In Brief
This article was originally published in The Gray Sheet
Executive Summary
St. Jude EonC approval: St. Paul, Minn., firm announces FDA and EU approval of EonC, "the first extended-life primary cell (non-rechargeable) neurostimulator for chronic pain." Device features NeuroDynamix technology to deliver stimulation more efficiently, advanced programming capability to let patients adjust therapy strength in eight pain areas and constant current circuitry that automatically adjusts power output for consistent therapy over time, the company says. St. Jude gained the original Eon, approved in 2005, in its acquisition of Advanced Neuromodulation Systems later that year (1"The Gray Sheet" May 9, 2005, p. 16)
You may also be interested in...
ANS Stimulates Wall Street With New Rechargeable IPG, Parkinson’s Trial
Advanced Neuromodulation Systems expects the full roll-out of its Eon rechargeable implantable pulse generator in the second half of the year to help propel a continued rebound of the firm's stock
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.